Notably, single case studies with BCC patients receiving nivolumab or pembrolizumab (two clinically approved anti-PD-1 antibodies) have already yielded promising results, suggesting that the use of immune checkpoint inhibitors can provide a therapeutic benefit in HH/GLI-driven non-melanoma skin cancer [74, 76, 89, 90]. This evidence concerns the gene GLI1 and skin basal cell carcinoma.